Impact of UTUC on Outcomes of Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin

Autor: S. F. Matin, N Brooks, J Matulay, N Navai, HB Grossman, Colin P.N. Dinney, Ashish M. Kamat, PJ Hensley, KK Bree

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 38:898

Introduction There is a paucity of information regarding impact of upper tract urothelial carcinoma (UTUC) on the patterns of BCG response in patients with NMIBC treated with BCG. We present the clinicopathological characteristics of patients with a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7fb0d93ee181be020e2e41b37e1e13ac
https://doi.org/10.1016/j.urolonc.2020.10.028

Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network

Autor: Lianes P, Charytonowicz E, Cordon-Cardo C, Yves Fradet, Hb, Grossman, Gp, Hemstreet, Fm, Waldman, Chew K, Ll, Wheeless, Faraggi D

Publikováno v: Europe PubMed Central

A cohort of 109 patients with primary transitional cell carcinomas, stages T2-T3, grade 2 or higher, was identified and further divided into two groups based on lymphatic metastasis at the time of cystectomy (n = 57 cases) or absence of detectable me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::48261fc9fd82069c828443a39adfe447
https://pubmed.ncbi.nlm.nih.gov/9607586

Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network

Autor: Lm, Mcshane, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Yves Fradet, Hb, Grossman, Peng A, Se, Taube, Fm, Waldman

Publikováno v: Europe PubMed Central

The National Cancer Institute Bladder Tumor Marker Network conducted a study to evaluate the reproducibility of immunohistochemistry for measuring p53 expression in bladder tumors. Fifty paraffin blocks (10 from each of the five network institutions)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::db3504eda95a8ac2c7daa140bebabc99
http://europepmc.org/abstract/med/10815908

All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors.

Autor: Bree KK; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Hensley PJ; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Lobo N; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Brooks NA; UPMC Urology of Central Pennsylvania, Harrisburg, Pennsylvania., Nogueras-Gonzalez GM; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas., Guo CC; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Navai N; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Grossman HB; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Dinney CP; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: The Journal of urology [J Urol] 2022 Aug; Vol. 208 (2), pp. 284-291. Date of Electronic Publication: 2022 Jun 30.

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.

Autor: Hensley PJ; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bree KK; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brooks N; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Matulay J; Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Li R; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA., Nogueras-Gonzalez GM; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nagaraju S; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Navai N; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grossman HB; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dinney CP; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org.

Publikováno v: European urology oncology [Eur Urol Oncol] 2022 Jun; Vol. 5 (3), pp. 347-356. Date of Electronic Publication: 2021 Apr 29.